Krishna Institute of Medical Sciences Limited has informed stock exchanges about an upcoming board meeting scheduled for March 11, 2026, to deliberate on a significant fund raising proposal. The company filed the intimation on March 6, 2026, in compliance with SEBI LODR Regulations.

Board Meeting Details

The meeting has been convened under Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will consider and evaluate proposals for raising funds through equity share issuance.

Fund Raising Methodology

The company plans to raise funds through multiple potential avenues. The board will evaluate issuance of equity shares in one or more tranches through various mechanisms.

Proposed Fund Raising Options:

• Qualified Institutions Placements (QIP)
• Rights issue
• Other permissible modes or combination thereof

The fund raising will be conducted in accordance with the Companies Act, 2013 and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Approval Requirements

The fund raising proposal is subject to multiple levels of approval and regulatory compliance. The board retains discretion over terms and conditions while ensuring adherence to statutory requirements.

The board will also consider convening a shareholders' meeting to seek approval from company members for the proposed fund raising initiative. The final terms, conditions, and manner of fund raising will be determined by the board based on market conditions and regulatory requirements.

Krishna Institute of Medical Sciences Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, demonstrating strong operational performance and strategic expansion initiatives. The healthcare services provider has also completed regulatory compliance requirements by filing necessary documentation with stock exchanges regarding newspaper publication of its financial results.

Consolidated Financial Performance

The company delivered robust consolidated financial results for Q3FY26, with revenue from operations showing substantial growth compared to the previous year.

For the nine-month period ended December 31, 2025, the company maintained strong momentum with consolidated revenue from operations reaching Rs 28,300 million compared to Rs 22,381 million in the corresponding period of the previous year, marking a growth of 26.43%.

Standalone Results Show Consistent Growth

The standalone financial performance also reflected positive trends, with the parent company showing healthy operational metrics.

The standalone revenue growth of 27.17% in Q3FY26 demonstrates the core business strength, while the nine-month standalone revenue reached Rs 12,453 million compared to Rs 10,382 million in the previous year.

Strategic Investment in Material Subsidiary

The Board of Directors approved a significant strategic initiative involving increased investment in Sarvejana Healthcare Private Limited, the company's material subsidiary operating Sunshine Hospital.

Sunshine Hospital, incorporated on December 3, 2008, operates as a specialized orthopedic hospital with joint replacement as its core service, supplemented by other high-end healthcare facilities including cardiology and transplant services.

Regulatory Compliance and Publication

The company has fulfilled its regulatory obligations under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial results were published on February 6, 2026, in Financial Express (English) and Navatelangana (Telugu) newspapers. Company Secretary Nagajayanthi J.R. filed the compliance documentation with BSE and NSE on February 7, 2026, confirming adherence to disclosure requirements. The published results are also accessible on the company's website under investor disclosures section.